课题基金 / 基金详情

Macrophage Gene Expression in Mucosal Inflammation

Macrophage Gene Expression in Mucosal Inflammation
粘膜炎症中的巨噬细胞基因表达
批准号:
7896861
负责人:
SCOTT E PLEVY
金额:
$28.01万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-09-01 至 2011-07-31

项目摘要

项目成果

SCOTT E PLEVY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Experiments proposed in this application will explore the role of macrophage activation in the pathogenesis of the inflammatory bowel diseases (IBD). We will focus on the molecular regulation of IL-12 p40 in macrophages as one of the most biologically significant events in T-helper1 (Th1)-mediated chronic inflammation. We have recently described a novel composite element in the IL-12 p40 promoter that interacts with members of the nuclear factor of activated T cells (NFAT) and interferon regulatory factor (IRF) families of transcription factors. This control element is involved in the synergistic induction of IL-12 p40 promoter activity by bacterial products and interferon-y (IFN-y), and is an important target for inhibition of IL- 12 p40 gene expression through several signal transduction pathways. The overall goal of this proposal is to understand the molecular regulation of IL-12 p40 in experimental models of IBD. Experiments will elucidate the role of two newly appreciated anti-inflammatory signal transduction pathways in macrophages: Heme oxygenase-1 (HO-1) and phosphatidylinositol-3-kinase (PI3K). We hypothesize that these anti-inflammatory pathways converge through regulation of NFAT/IRF interactions at the IL-12 p40 promoter. By inhibiting IL-12 p40, HO-1 and PI3K serve as molecular "brakes" for macrophage activation that may limit the extent and duration of chronic intestinal inflammation. lnterleukin-12 (IL-12) is an inflammatory protein that has been demonstrated to be important in the progression of human Crohn's disease (CD). In this application, we will test therapeutic interventions in mouse models of CD to inhibit IL-12 production by cells of the immune system called macrophages. Studies in this application will give us important information about immune inhibitory pathways that may be defective in human IBD and may lead to new therapeutic interventions in human IBD that target macrophages and IL- 12.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI: 10.4049/jimmunol.1103558
发表时间: 2012-05-15
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者: [Gowdy KM, Cardona DM, Nugent JL, Giamberardino C, Thomas JM, Mukherjee S, Martinu T, Foster WM, Plevy SE, Pastva AM, Wright JR, Palmer SM]
通讯作者: Palmer SM
DOI: 10.1084/jem.20051047
发表时间: 2005-12-19
期刊: The Journal of experimental medicine
影响因子: --
作者: [Hegazi RA, Rao KN, Mayle A, Sepulveda AR, Otterbein LE, Plevy SE]
通讯作者: Plevy SE
Innate immune receptor genetic polymorphisms in pouchitis: is CARD15 a susceptibility factor?
储袋炎先天免疫受体基因多态性:CARD15是易感因素吗?
DOI: 10.1097/01.mib.0000186407.25694.cf
发表时间: 2005
期刊: Inflammatory bowel diseases
影响因子: 4.9
作者: [Meier,CarmenB, Hegazi,RefaatA, Aisenberg,James, Legnani,PeterE, Nilubol,Naris, Cobrin,GenaM, Duerr,RichardH, Gorfine,StephenR, Bauer,JoelJ, Sachar,DavidB, Plevy,ScottE]
通讯作者: Plevy,ScottE
The role of macrophages and dendritic cells in the initiation of inflammation in IBD.
巨噬细胞和树突状细胞在 IBD 炎症引发中的作用。
DOI: 10.1097/mib.0b013e3182a69dca
发表时间: 2014-01
期刊: Inflammatory bowel diseases
影响因子: 4.9
作者: [Steinbach EC, Plevy SE]
通讯作者: Plevy SE
6
    IMMUNOTECHOLOGIES CORE
    Macrophage Gene Expression in Mucosal Inflammation
    Validation of a Novel NF-kB Inhibitor in Inflammatory Bowel Disease
    • 批准号:
      8251611
    • 项目类别:
    • 资助金额:
      $69.81万
    • 财政年份:
      2006
    • 负责人:
      SCOTT E PLEVY
    • 依托单位:
    Validation of a Novel NF-KB Inhibitor in Murine IBD
    • 批准号:
      7053160
    • 项目类别:
    • 资助金额:
      $21.7万
    • 财政年份:
      2006
    • 负责人:
      SCOTT E PLEVY
    • 依托单位:
    海外基金